Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kongo vs LumiMeds

By GLP-1 ScorecardUpdated

Kongo
Site position #19

Higher grade

LumiMeds
Site position #292

Lower grade

Score comparison

Kongo has the higher recorded score — 83.8/100 to 63.2/100.

Kongo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Cheap semaglutide ($119) but a steeper tirzepatide step-up ($229); verified, nationwide.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueKongo +9
86
77
Dose & formulationKongo +16
80
64
Clinical oversightKongo +29
84
55
Labs & monitoringKongo +29
82
53
FulfillmentKongo +22
87
65
Contract termsKongo +30
85
55
Kongo · top barLumiMeds · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricKongoLumiMeds
WeighScore83.8/10063.2/100
GradeBC
Site position#19#292
Semaglutide$119/mo$133/mo (starting dose, compounded)
Tirzepatide$229/mo$133/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Kongo

Site position #19 · B

Strengths

  • $119 semaglutide
  • All 50 states, LegitScript-verified
  • Both molecules

What to consider

  • Tirzepatide jumps to $229/mo
  • Injection-only
  • Monitoring detail sparse
LumiMeds

Site position #292 · C

FDAWarning letter issued to Lumimeds in September 2025. See the FDA warning-letter database.

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

What to consider

  • Limited public information on program details
  • FDA issued Lumimeds a warning letter in September 2025; the letter is public in FDA's warning-letter database

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard